India-based biotechnology firm Mylab Discovery Solutions has collaborated with Hemex Health to develop next-generation diagnostic solutions for the Point-of-Care (POC) testing of coronavirus and other diseases.

As part of the deal, Mylab will involve in the development of test assays, while US-based medical diagnostic device company Hemex will offer its Gazelle POC testing platform and expertise.

The portable diagnostic device and test assays facilitate testing at any location, as well as in a wide range of environmental conditions. They also help to avoid the shipping of the sample and enable rapid result for the patients.

Both companies will also focus on the development of Fluorescence Immunoassay (FIA) and Electrophoresis-based diagnostic solutions.

These tests are said to be more sensitive than the normal rapid antigen tests and may result in less false negatives.

Mylab and Hemex Health will jointly launch the diagnostic solution in international markets including the US, Europe and Asia.

The partnership will also bring together deep knowledge in molecular diagnostic technology, product ideation, and new technology development and deployment to boost testing capabilities for Covid-19 across the world.

Mylab and Hemex Health are planning to launch the first product from the technology partnership by November this year.

Hemex Health, which is supported by TiE Global Angels and Cleveland Clinic, supplies a point-of-care sickle cell test on their Gazelle Diagnostic Device in nine countries.

Supported by Adar Poonawalla of Serum Institute of India, Mylab is engaged in the development of diagnostics solutions. It already offers CoviSelf self-test kit for Covid-19.